Full Press Release Details
PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.
Barclays Global Investor Conference:
| Presentation Date: | Wednesday, March 16, 2022 |
| Presentation Time: | 9:00 AM Eastern Time |
| Webcast: | https://barclays.webcasts.com/starthere.jsp?ei=1533028&tp_key=1d6b22fa07&tp_special=8 |
Following the live presentation, a replay of the presentation will be available under the Investor section of PolyPid’s website at https://investors.polypid.com/events-and-presentations/events and archived for 30 days thereafter. Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.
PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Dikla Czaczkes Akselbrad